Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
Adds to the growing body of evidence supporting DQS for dd-cfDNA analysis in solid organ transplant
AUSTIN, Texas, May 07, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new study1 evaluating the performance of Prospera Heart with DQS to detect allograft rejection.
Prospera with DQS leverages a two-threshold algorithm, combining the traditional donor fraction (dd-cfDNA %, measuring dd-cfDNA as a fraction of total cfDNA) and donor quantity score (DQS, estimating the total quantity of dd-cfDNA in the blood). This method delivers a single result for risk assessment of both antibody mediated rejection (AMR) and acute cellular rejection (ACR).
In the study, 808 Prospera Heart test samples were obtained from 187 heart transplant patients alongside paired endomyocardial biopsies. Prospera with DQS was compared to dd-cfDNA %-alone to assess the detection of biopsy-proven allograft rejection. The study highlights the following performance improvements demonstrated by Prospera with DQS, including:
Sensitivity increased from 78.2% to 86.5%.
Specificity increased from 76.9% to 83.6%.
Area under the curve (AUC) increased from 0.865 to 0.881
A reduction in false positive cases of 37.3%
"This publication provides evidence that combining dd-cfDNA % with DQS improves the accuracy of dd-cfDNA testing for acute rejection over dd-cfDNA %-alone," said Josef Stehlik, M.D., M.P.H., one of the study investigators and medical director of the Heart Transplant Program and co-chief of the Advanced Heart Failure Program at the University of Utah. "It is encouraging to see that this novel approach significantly reduced false positive results and will help to obviate unnecessary biopsies in clinical care. This is another step in providing enhanced care for heart transplant patients using noninvasive tools to determine risk of rejection."
This data confirms the growing body of evidence for the utilization of DQS when analyzing dd-cfDNA in solid organ transplant, including a study evaluating DQS in kidney transplant (Halloran et al). Natera has also demonstrated the value of DQS in the supplemental data from its 2022 DEDUCE study2 in Prospera Heart, as well as recently announced data from the DEFINE-HT study.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Comstock Welcomes Perspire Sauna Studio to The Hartford
RESTON, Va.--(BUSINESS WIRE)--Comstock Holding Companies, Inc. (Nasdaq: CHCI) ('Comstock'), a leading asset manager, developer, and operator of mixed-use and transit-oriented properties in the Washington, D.C. region, announced today that Perspire Sauna Studio has signed a lease to occupy 1,700 square feet of street-level retail space at The Hartford, located at 3101 Wilson Boulevard in Arlington, Virginia. Perspire Sauna Studio offers innovative recovery and self-care experiences using full-spectrum infrared sauna therapy and medical-grade red light therapy. Private sauna suites offer personalized sessions for detoxification, immune support, improved circulation, enhanced skin health, and mental clarity in a serene, spa-like environment. Joining over 70 locations nationwide, this location will be Perspire Sauna Studio's second location in the DMV region and is targeted to open by the end of 2025. 'Bringing Perspire Sauna Studio to Clarendon is another exciting step in our vision to expand access to the wellness benefits of infrared sauna and red-light therapy across Northern Virginia,' said Michael Baffa, Co-Owner of Perspire Sauna Studio Clarendon. 'From detoxification and improved circulation to mental clarity and relaxation, our private, spa-like suites are designed to help guests feel their best. We look forward to introducing the Clarendon community to a personalized wellness experience that's as inviting as it is effective.' Perspire Sauna Studio is the latest addition to The Hartford's curated mix of retailers, joining Cut7 Sports and Fitness Training, East West Café, Kilwins Chocolate and Ice Cream Shop (opening this September), and Paris Baguette (scheduled to open later this fall). 'The addition of Perspire Sauna Studio to The Hartford compliments its already impressive roster of retail providers,' said Tim Steffan, Chief Operating Officer of Comstock. 'We remain committed to promoting wellness-driven, lifestyle retail offerings that provide elevated experiences for tenants, visitors, and the surrounding community.' Located just steps from the Clarendon Metro Station, The Hartford is a nine-story Class A office building that offers unparalleled amenities in the heart of Arlington's vibrant Clarendon neighborhood. The property features modern office space and easy access to premium retail and key transportation routes. About Comstock Founded in 1985, Comstock is a leading asset manager, developer, and operator of mixed-use and transit-oriented properties in the Washington, D.C. region. With a managed portfolio comprising approximately 10 million square feet at full build-out and including stabilized and development assets strategically located at key Metro stations, Comstock is at the forefront of the urban transformation taking place in the fastest-growing segments of one of the nation's best real estate markets. Comstock's developments include some of the largest and most prominent mixed-use and transit-oriented projects in the mid-Atlantic region, as well as multiple large-scale public-private partnership developments. For more information, please visit
Yahoo
2 hours ago
- Yahoo
Why BeautyHealth (SKIN) Stock Is Up Today
What Happened? Shares of skincare company BeautyHealth (NASDAQ:SKIN) jumped 3.2% in the afternoon session after the release of a favorable Consumer Price Index (CPI) report, which showed inflation cooling more than anticipated. The July report from the Bureau of Labor Statistics indicated a year-over-year inflation rate of 2.7%, just below the 2.8% economists had forecast. This suggests that price pressures on consumers may be easing. Particularly beneficial for the sector was the news that the food index remained flat, with grocery prices even declining by 0.1% month-over-month. This development is seen as a positive for the profitability of food, beverage, and personal care companies, as lower input costs and increased consumer purchasing power could boost sales. A Federal Reserve official's comments on the same day, noting that consumer spending fundamentals remain solid, further bolstered investor confidence in the sector's resilience. After the initial pop the shares cooled down to $2.26, up 2.2% from previous close. Is now the time to buy BeautyHealth? Access our full analysis report here, it's free. What Is The Market Telling Us BeautyHealth's shares are extremely volatile and have had 73 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 4 days ago when the stock gained 20.6% on the news that the company reported second-quarter financial results that significantly beat analyst expectations on profitability and raised its full-year outlook. The company posted earnings per share of $0.03, decisively beating analyst estimates of a $0.05 loss, while revenue of $78.2 million also topped forecasts. Although total sales decreased by 13.7% compared to the previous year, investors were encouraged by a significant improvement in profitability, with adjusted EBITDA of $13.9 million significantly exceeding the consensus estimate of $3.59 million. The strong results were driven by a notable increase in gross profit margin, which expanded by 17.6 percentage points year on year. Bolstered by this performance, Beauty Health raised its full-year guidance for both net sales and adjusted EBITDA, signaling confidence in its ongoing strategy. BeautyHealth is up 40.7% since the beginning of the year, and at $2.26 per share, it is trading close to its 52-week high of $2.28 from July 2025. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Business Wire
3 hours ago
- Business Wire
Industry Leaders, Policymakers to Gather at Annual DC-based SPIE Photonics Industry Summit on 18 September
BELLINGHAM, Wash.--(BUSINESS WIRE)--On 18 September, in Washington, DC, SPIE, the international society for optics and photonics, will host its fourth annual Photonics Industry Summit. The event will bring together leaders from the optics and photonics community, executives from related businesses, high-level US government agency representatives, and US congressional representatives. Collectively, they will be sharing their plans and expectations for optics and photonics-related programs in key areas such as directed energy, semiconductors, space, biotechnology, quantum, and other emerging technologies. The featured speakers include: US Congressperson Joe Morelle NASA Acting Deputy Associate Administrator, Science Mission Directorate Mark Clampin NIH Director of the National Institutes of Biomedical Imaging and Bioengineering Bruce Tromberg Akin Senior Counsel Matthew S. Borman NSF Directorate for Technology, Innovation, and Partnerships Kerri Dugan US Department of Energy Program Director, Advanced Research Projects Agency – Energy Emily R. Kinser Defense Innovation Unit Technical Program Manager Jeffrey Wright SPIE CEO Kent Rochford Prior to the summit SPIE will host a Congressional Reception, which will be held on Capitol Hill at the Rayburn House Office Building, from 5:00 PM-8:00 PM on 17 September. No additional registration is required for this opportunity to network, speak directly with congressional representatives, and advocate on behalf of the photonics industry. 'I'm very much looking forward to this year's SPIE Photonics Industry Summit,' says SPIE Director of Government Affairs Jennifer O'Bryan. 'The constantly changing policy landscape can be challenging for company executives. This unique opportunity allows direct access to a range of senior government officials with significant budget authority. Additionally, the complementary congressional reception offers a truly unique opportunity to engage with your elected representatives.' The event is sponsored by Hamamatsu, Leonardo, Optimax, Sydor Optics, Thorlabs, and TOPTICA. For more information and to register for the SPIE Photonics Industry Summit, please visit our website. Be sure to register early: prices will increase after 5 September. About SPIE SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, we have invested more than $25 million in the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development.
